

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

[CGDB](#)

RRID:SCR_011959

Type: Tool

Proper Citation

CGDB (RRID:SCR_011959)

Resource Information

URL: <http://sbc.bioch.ox.ac.uk/cgdb/>

Proper Citation: CGDB (RRID:SCR_011959)

Description: A database of membrane protein/lipid interactions by coarse-grained molecular dynamics simulations.

Abbreviations: CGDB

Synonyms: Coarse Grained Database, Coarse-Grained Database, CG Database

Resource Type: data set, data or information resource

Defining Citation: [PMID:18937097](#), [PMID:18208379](#)

Keywords: protein, image, coarse-grained, molecular dynamics, membrane protein

Funding: BBSRC

Availability: Acknowledgement requested

Resource Name: CGDB

Resource ID: SCR_011959

Alternate IDs: OMICS_01608

Record Creation Time: 20220129T080307+0000

Record Last Update: 20260801T191205+0000

Ratings and Alerts

No rating or validation information has been found for CGDB.

No alerts have been found for CGDB.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hage Chehade C, et al. (2025) Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4101.

Boos LA, et al. (2025) Precision Oncology Program (POP), an observational study using real-world data and imaging mass cytometry to explore decision support for the Molecular Tumor Board: study protocol. BMJ open, 15(3), e096591.

Du J, et al. (2025) Exploring the association between circadian rhythms and osteoporosis: new diagnostic and therapeutic targets identified via machine learning. Frontiers in molecular biosciences, 12, 1614221.

Rizzo M, et al. (2025) The genomic landscape of metastatic clear-cell renal cell carcinoma and its prognostic value: a comprehensive analysis of a large real-world clinico-genomic database. ESMO open, 10(3), 104294.

Li H, et al. (2025) Comprehensive Analysis Reveals the Potential Diagnostic Value of Biomarkers Associated With Aging and Circadian Rhythm in Knee Osteoarthritis. Orthopaedic surgery, 17(3), 922.

Bilen MA, et al. (2025) Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer. Advances in therapy, 42(8), 3945.

Zhang Y, et al. (2025) Jet lag-induced circadian disruption elevates glioma risk by altering molecular profiles in distinct brain regions. Discover oncology, 16(1), 1410.

Radhakrishna U, et al. (2024) DNA methylation patterns of circadian and ultradian genes are altered in the peripheral blood of patients with hidradenitis suppurativa. Frontiers in immunology, 15, 1475424.

Yorio J, et al. (2024) Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer. JCO precision oncology, 8, e2300292.

Shui IM, et al. (2024) Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate cancer and prostatic diseases, 27(4), 728.

Bhave MA, et al. (2024) Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. *Breast cancer research and treatment*, 207(3), 599.

Shi Y, et al. (2024) Mining key circadian biomarkers for major depressive disorder by integrating bioinformatics and machine learning. *Aging*, 16(12), 10299.

Palatinszky M, et al. (2024) Growth of complete ammonia oxidizers on guanidine. *Nature*, 633(8030), 646.

Waliany S, et al. (2024) Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database. *Cancer medicine*, 13(24), e70272.

Quintanilha JCF, et al. (2023) Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. *JCO precision oncology*, 7, e2300092.

Reichert ZR, et al. (2023) Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. *Annals of oncology : official journal of the European Society for Medical Oncology*, 34(1), 111.

So WV, et al. (2023) Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. *Journal for immunotherapy of cancer*, 11(2).

Wang Q, et al. (2023) Circadian Genes MBOAT2/CDA/LPCAT2/B4GALT5 in the Metabolic Pathway Serve as New Biomarkers of PACA Prognosis and Immune Infiltration. *Life (Basel, Switzerland)*, 13(5).

Ton TGN, et al. (2022) Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(13), 2844.

Sammons S, et al. (2022) APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. *JCO precision oncology*, 6, e2200149.